History of allogeneic organ transplantation
CRITERIA FOR ALLOGENEIC TRANSPLANTATION
Prior autologous or allogeneic organ or tissue transplantation
History of allogeneic organ transplantation.
Patients who are candidates for allogeneic transplantation, have a suitable donor, and are willing to undergo transplantation
Anticipated liver transplantation
Prior allogeneic transplantation
Previous allogeneic or autologous hematopoietic cell transplantation or solid organ transplantation
Patients with prior orthotropic liver transplantation
History of allogeneic organ transplantation
Allogeneic hematopoietic cell transplantation within 5 years of study drug administration
Patients who have undergone prior liver transplantation are ineligible
PHASE I: Patients who are between T+40 and T+100 after allogeneic transplantation
PHASE I: Patients who have evidence of donor chimerism after allogeneic transplantation
PHASE II: Patients who are between T+40 and T+100 after allogeneic transplantation
PHASE II: Patients who have >= 80% donor chimerism after allogeneic transplantation
ADDITIONAL INCLUSION CRITERIA PERTINENT ONLY FOR PATIENTS WITH PRIOR ALLOGENEIC TRANSPLANTATION:
Prior hematopoietic transplantation is allowed (autologous and/or allogeneic)
Patients with any of the following hematologic malignancies who are considered to be eligible for allogeneic transplantation:
Prior history of allogeneic hematopoietic cell transplantation
Patients who have undergone prior liver transplantation are ineligible
Relapsed after allogeneic transplantation
Prior hematopoietic transplantation is allowed (autologous and/or allogeneic)
Use of any of the following after transplantation and prior to starting study therapy:
Prior high dose chemotherapy for autologous hematopoietic cell transplantation or prior allogeneic transplantation
Relapsed malignancy after transplantation
Prior allogeneic or autologous transplantation
Prior allogeneic hematopoietic progenitor cell transplantation
Transplantation for AML (allogeneic or autologous) allowed unless within 90 days of study entry
Relapsed after allogeneic transplantation
Patients with B-cell hematological malignancies who are eligible for allogeneic transplantation
At least 60 days from day of transplantation
Prior autologous or allogeneic organ or tissue transplantation
Patients considered for transplantation must have a sufficient graft as based on current criteria of the University of Minnesota Blood and Marrow Transplantation Program
Time available (at least 12 weeks) for treatment of hepatitis C prior to autologous or allogeneic transplantation
History of allogeneic organ transplantation
History of allogeneic organ transplantation.
Prior autologous or allogeneic organ or tissue transplantation
Prior autologous or allogeneic transplantation for any disease
No prior autologous or allogeneic organ or tissue transplantation
History of allogeneic organ transplantation.
Prior hematopoietic cell transplantation allogeneic or autologous (A prior autologous HCT will be allowed as long as it was part of tandem transplantation).
Prior allogeneic hematopoietic cell transplantation
ALLOGENEIC TRANSPLANTATION:
Subjects who are candidates for allogeneic transplantation, have a suitable donor, and are willing to undergo transplantation
Previous liver transplantation
Prior allogeneic transplantation
Patients who have undergone liver transplantation are excluded
Prior allogeneic transplantation
Patients must be between 2-6 months post-transplantation at the time of study registration
Patients who have received liver transplantation
History of allogeneic organ transplantation;
History of allogeneic organ transplantation
Subjects who relapse after allogeneic transplantation;
Patients who have undergone prior liver transplantation are ineligible
Prior liver transplantation and on immunosuppression
Patients that underwent allogeneic transplantation as a treatment of graft failure
Hepatitis A, B and C status will be tested prior to therapy, but results will not exclude patients from participation (if positive, patients will be told they are at higher risk of adverse effects from allogeneic transplantation)
No prior autologous or allogeneic hematopoietic cell transplantation
Patients that underwent allogeneic transplantation as a treatment of graft failure
Patient must meet eligibility criteria for allogeneic transplantation
Prior allograft transplantation including liver transplantation.
Immunocompromised, as defined by one of the following: Autologous or Allogeneic hematopoietic cell transplantation (HSCT); Lung or lung-heart transplantation; Subjects treated with chemotherapy for hematologic malignancies; Subjects treated with chemotherapy for solid tumor malignancies
Has received a prior allogeneic organ or tissue transplantation
The participant has received a prior autologous or allogeneic organ or tissue transplantation.
Patients who have undergone prior allogeneic transplantation are eligible provided that their transplant day 0 is > 6 months from their first dose of study drug
Transplantation of PBSC
Patients must have undergone an autologous transplant =< 12 months prior to allogeneic transplantation or have received multi-agent or immunosuppressive chemotherapy within 3 months of the preparative regimen
Prior allogeneic transplantation
Patients must have a hematologic malignancy for which allogeneic hematopoietic peripheral blood cell transplantation is deemed clinically appropriate. Eligible diseases and stages include the following:
Prior allogeneic hematopoietic cell transplantation (HCT)
Hematologic disorder requiring allogeneic hematopoietic cell transplantation
Transplantation with PBSC
Prior allogeneic transplantation
